Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.90 |
| ▸ | GSK3B | P49841 | 13/20 | 0.90 |
| ▸ | CLK2 | P49760 | 3/20 | 0.90 |
| ▸ | CLK3 | P49761 | 3/20 | 0.90 |
| ▸ | WNT1 | P04628 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945234 | 0.95 | DYRK1A (1.00) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20945251 | 0.90 | DYRK1A (0.88) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20949013 | 0.90 | DYRK1A (0.72) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20949769 | 0.89 | DYRK1A (0.71) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20945339 | 0.88 | DYRK1A (1.00) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20951759 | 0.87 | DYRK1A (0.69) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20947641 | 0.87 | DYRK1A (0.69) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20968865 | 0.86 | DYRK1A (0.81) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20945328 | 0.86 | DYRK1A (1.00) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL20945322 | 0.86 | DYRK1A (1.00) | DYRK1AGSK3BCLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744128-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200155540-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-10413537-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190125741-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155540-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 10/4885CLK2 36/4885 |
| US-10744128-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 10/4885CLK2 36/4885 |
| US-10413537-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 10/4885CLK2 36/4885 |
| US-20190125741-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 10/4885CLK2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.